484 Results

People

  1. Baselga
    Baselga
  2. Hyman
    Hyman
  3. Hudis
    Hudis
  4. Berger
    Berger
  5. Chandarlapaty
    Chandarlapaty
  6. Solit
    Solit
  7. Norton
    Norton
  8. Scaltriti
    Scaltriti
  9. Dickler
    Dickler
  10. Razavi
    Razavi

Groups

  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)
  7. Survivorship Research (88)
  8. Department of Pathology and Laboratory Medicine (79)
  9. Sloan Kettering Institute Postdocs (75)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (69)
  1. "Jose Baselga"
Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. Jose Baselga (484)
  2. David Hyman (68)
  3. Maurizio Scaltriti (63)
  4. Clifford Hudis (57)
  5. Michael Berger (56)
  6. Larry Norton (51)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): A multicenter, two-cohort, non-randomized phase II trial
    Journal Article

    Pascual, T.; Oliveira, M.; Villagrasa, P.; Ortega, V.; Paré, L.; Bermejo, B.; Morales, S.; Amillano, K.; López, R.; Galván, P.; more...
    npj Breast Cancer (2021)

    Fulltext@MSK | Save
  • Cell line-specific network models of ER(+) breast cancer identify potential PI3Kα inhibitor resistance mechanisms and drug combinations
    Journal Article

    Zañudo, J. G. T.; Mao, P.; Alcon, C.; Kowalski, K.; Johnson, G. N.; Xu, G.; Baselga, J.; Scaltriti, M.; Letai, A.; Montero, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Patient-reported function, health-related quality of life, and symptoms in APHINITY: Pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer
    Journal Article

    Bines, J.; Clark, E.; Barton, C.; Restuccia, E.; Procter, M.; Sonnenblick, A.; Fumagalli, D.; Parlier, D.; Arahmani, A.; Baselga, J.; more...
    British Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Utility of serial cfDNA NGS for prospective genomic analysis of patients on a phase I basket study
    Journal Article

    Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, D. S.; Houck-Loomis, B.; You, D.; Samoila, A.; Schiavon, G.; more...
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save
  • Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
    Journal Article

    Smyth, L. M.; Batist, G.; Meric-Bernstam, F.; Kabos, P.; Spanggaard, I.; Lluch, A.; Jhaveri, K.; Varga, A.; Wong, A.; Schram, A. M.; more...
    npj Breast Cancer (2021)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Oncologic therapy shapes the fitness landscape of clonal hematopoiesis
    Meeting Abstract

    Bolton, K. L.; Ptashkin, R. N.; Gao, T.; Braunstein, L.; Devlin, S. M.; Patel, M.; Berthon, A.; Syed, A.; Yabe, M.; Coombs, C.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Compound PIK3CA mutations support a mutational dose-response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer
    Meeting Abstract

    Vasan, N.; Johnson, J.; Shao, H.; Razavi, P.; Gorelick, A.; Ladewig, E.; Antoine, A.; Shah, H.; Toska, E.; Xu, G.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer
    Journal Article

    Arruabarrena-Aristorena, A.; Maag, J. L. V.; Kittane, S.; Cai, Y.; Karthaus, W. R.; Ladewig, E.; Park, J.; Kannan, S.; Ferrando, L.; Cocco, E.; more...
    Cancer Cell (2020)

    Fulltext@MSK | Save
  • A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases
    Journal Article

    Xu, J.; Higgins, M. J.; Tolaney, S. M.; Come, S. E.; Smith, M. R.; Fornier, M.; Mahmood, U.; Baselga, J.; Yeap, B. Y.; Chabner, B. A.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save